One Drop CEO Jeff Dachis on helping people w/diabetes, partnering with Bayer, actionable data | E1022

Jason talks with One Drop CEO Jeff Dachis about his company's evolution, turning data into action, and their partnership with Bayer. They explore the role of software in medication management, the importance of in-house healthcare, and the current state of the diabetes epidemic. The discussion extends to the potential future of blood sugar monitoring and gene-therapy risks.

Speakers

AI Chat

Unidentified

Jason Calacanis

Host • 54%

Jeff Dachis

Guest • 44%

Chapters

0:00	Opening
0:47	Jason intros One Drop CEO Jeff Dachis
2:37	What was Jeff's original vision with One Drop? How has it evolved over time?
5:39	How did One Drop go from collecting data to making it actionable?
8:09	How important was getting the One Drop retail products into Apple stores?
9:46	Raising money as a hardware healthcare product
15:23	How did the Bayer partnership come about?
17:57	Have any major drug companies built software to manage what happens after taking medication?
21:19	What is the One Drop business today? How does coaching play into their product?
30:27	Who are One Drop's enterprise sales targets? Why don't more companies have health practitioners in-house?
36:37	Should employers be tied to healthcare?
40:04	What contributes most to the diabetes epidemic?
44:46	What are continuous glucose monitors? How do they help?
48:34	Why is insulin so expensive in the US compared to other countries?
51:47	Will we ever be able to know our blood sugar levels without intrusive hardware?
57:47	Will humans see average life-expansion into the 100's over the next few decades?
1:02:12	How gene-therapy becomes dangerous

Transcript

Clip

Loading transcript...